Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263941 | 0.94 | MEN1 (0.57) | SMN1; SMN2MEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL5262999 | 0.87 | DRD2 (0.54) | HTR2ADRD2HTR1AHTR7SLC6A4 | |
| SCHEMBL5268778 | 0.85 | MEN1 (0.48) | MEN1KMT2ADRD2HTR1AHTR7 | |
| SCHEMBL5265876 | 0.83 | SIGMAR1 (0.48) | HTR2AHTR2CDRD2HTR1AHTR7 | |
| SCHEMBL5263985 | 0.83 | SIGMAR1 (0.47) | MEN1KMT2AHTR1AHTR7 | |
| SCHEMBL5268003 | 0.81 | SIGMAR1 (0.53) | MEN1KMT2AHTR1AHTR7 | |
| SCHEMBL5264783 | 0.81 | DRD2 (0.51) | HTR2ADRD2HTR1AHTR7SLC6A4 | |
| SCHEMBL5270524 | 0.80 | MEN1 (0.54) | SMN1; SMN2MEN1ALDH1A1KMT2ADRD2 | |
| SCHEMBL5270523 | 0.79 | ADRA1B (0.54) | MEN1ALDH1A1KMT2AHTR1ASLC6A4 | |
| SCHEMBL5265422 | 0.78 | ADRA1D (0.57) | MEN1KMT2AHTR2CDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |